{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:53:38Z","timestamp":1781373218170,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007489","name":"Bausch + Lomb","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-024-06969-4","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:02:26Z","timestamp":1729695746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early adoption of triamcinolone acetonide suprachoroidal injection for uveitic macular edema: a physician survey"],"prefix":"10.1186","volume":"17","author":[{"given":"Christopher R.","family":"Henry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Warrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa Emami","family":"Naeini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Blinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Brevetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Dacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena R.","family":"Raiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana M.","family":"Rifkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"6969_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2147\/OPTH.S180580","volume":"13","author":"H Massa","year":"2019","unstructured":"Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol. 2019;13:1761\u201377.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"6969_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/09273948.2021.2017152","volume":"29","author":"ETE Cunningham","year":"2021","unstructured":"Cunningham ETE, Zierhut M. Vision loss in uveitis. Ocul Immunol Inflamm. 2021;29(6):1037\u20139.","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"6969_CR3","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","volume":"113","author":"CWTA Lardenoye","year":"2006","unstructured":"Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446\u20139.","journal-title":"Ophthalmology"},{"key":"6969_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/DDDT.S166092","volume":"13","author":"S Koronis","year":"2019","unstructured":"Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG. Update in treatment of uveitic macular edema. Drug Des Devel Ther. 2019;13:667\u201380.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"6969_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/aos.14042","volume":"97","author":"Z Habot-Wilner","year":"2019","unstructured":"Habot-Wilner Z, Noronha G, Wykoff CC. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019;97(5):460\u201372.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"6969_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/pharmaceutics13020288","volume":"13","author":"C-R Wan","year":"2021","unstructured":"Wan C-R, Muya L, Kansara V, Ciulla TA. Suprachoroidal delivery of small molecules, nanoparticles, gene and cell therapies for ocular diseases. Pharmaceutics. 2021;13(2):288.","journal-title":"Pharmaceutics"},{"key":"6969_CR7","volume-title":"Acetonide injectable suspension), for suprachoroidal use [package insert]","author":"XIPERE (triamcinolone","year":"2022","unstructured":"XIPERE (triamcinolone. Acetonide injectable suspension), for suprachoroidal use [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc.; 2022."},{"issue":"11","key":"6969_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/tvst.9.11.27","volume":"9","author":"C-R Wan","year":"2020","unstructured":"Wan C-R, Kapik B, Wykoff CC, et al. Clinical characterization of suprachoroidal injection procedure utilizing a microinjector across three retinal disorders. Transl Vis Sci Technol. 2020;9(11):27.","journal-title":"Transl Vis Sci Technol"},{"key":"6969_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","volume":"126","author":"B Chiang","year":"2018","unstructured":"Chiang B, Jung JH, Prausnitz MR. The suprachoroidal space as a route of administration to the posterior segment of the eye. Adv Drug Deliv Rev. 2018;126:58\u201366.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"6969_CR10","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","volume":"127","author":"S Yeh","year":"2020","unstructured":"Yeh S, Khurana RN, Shah M, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology. 2020;127(7):948\u201355.","journal-title":"Ophthalmology"},{"issue":"6","key":"6969_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/bjophthalmol-2020-318019","volume":"106","author":"CR Henry","year":"2022","unstructured":"Henry CR, Shah M, Barakat MR, et al. Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA). Br J Ophthalmol. 2022;106(6):802\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"6969_CR12","first-page":"1139","volume":"106","author":"RN Khurana","year":"2022","unstructured":"Khurana RN, Merrill P, Yeh S, et al. Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). Br J Ophthalmol. 2022;106(8):1139\u201344.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"6969_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ajo.2010.08.039","volume":"151","author":"AE Green-Simms","year":"2011","unstructured":"Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol. 2011;151(2):329\u201332.","journal-title":"Am J Ophthalmol"},{"issue":"01","key":"6969_CR14","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1055\/s-0039-1688912","volume":"11","author":"JJ Liechty","year":"2019","unstructured":"Liechty JJ, Wilkinson MJ, Bowie EM. Assessment of intravitreal injection training among U.S.-based ophthalmology residents. J Acad Ophthalmol. 2019;11(01):e43\u20139.","journal-title":"J Acad Ophthalmol"},{"issue":"8","key":"6969_CR15","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.oret.2019.03.023","volume":"3","author":"R Chaturvedi","year":"2019","unstructured":"Chaturvedi R, Wannamaker KW, Riviere PJ, Khanani AM, Wykoff CC, Chao DL. Real-world trends in intravitreal injection practices among American retina specialists. Ophthalmol Retina. 2019;3(8):656\u201362.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"6969_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12886-023-02808-5","volume":"23","author":"BM Ali","year":"2023","unstructured":"Ali BM, Azmeh AM, Alhalabi NM. Suprachoroidal triamcinolone acetonide for the treatment of macular edema associated with retinal vein occlusion: a pilot study. BMC Ophthalmol. 2023;23(1):60.","journal-title":"BMC Ophthalmol"},{"key":"6969_CR17","doi-asserted-by":"crossref","unstructured":"Rujkorakarn P, Zhou A, Babiker F, Chang PY. Suprachoroidal triamcinolone injection in posterior scleritis: a case report [published online ahead of print July 14, 2023]. Ocul Immunol Inflamm 2023:1\u20134.","DOI":"10.1080\/09273948.2023.2232447"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-024-06969-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-024-06969-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-024-06969-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:06:49Z","timestamp":1729696009000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-024-06969-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6969"],"URL":"https:\/\/doi.org\/10.1186\/s13104-024-06969-4","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; this is a physician survey completed by the authors of this manuscript; therefore, no ethics approval or participant consent is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Competing interests: CRH reports being a consultant for Allergan, Alimera, Bausch + Lomb, Clearside Biomedical, Inc., and EyePoint Pharmaceuticals. SDW reports being a speaker for Apellis, Bausch + Lomb, Genentech\/Roche, Regeneron, and Spark Therapeutics. SDW reports being a consultant for Allergan, Astellis\/Iveric Bio, Bausch + Lomb, Castle Biosciences, EyePoint Pharmaceuticals\/Alimera, Genentech\/Roche, Ideaya Biosciences, Lupin, Novartis, and Regeneron. PEN reports receiving research and consulting fees from EyePoint Pharmaceuticals and Genentech. PEN is supported by the Knights Templar Eye Foundation, Inc. Career Starter grant. MAS reports receiving consulting fees from Aerie, Alimera, Allegro, Allergan, Eyepoint, Genentech, Kodiak, Novartis, Regeneron, and Santen; serving on the speakers\u2019 bureau for Allergan, Apellis, Genentech, Mallinckrodt, Novartis, Regeneron, and Spark; and performing contracted research for Aerie, Allegro, Allergan, DRCR, Genentech, Icon, Ionis, KalVista, Kodiak, Novartis, Opthea, Optos, Regeneron, Santen, Senju, and Sydnexis. Survey participants (CRH, SDW, PYC, DJW, PEN, KJB, MSD, DSC, VRR, LMR, MS, and MAS) received an honorarium from Bausch & Lomb Americas, Inc. TB and MY are employees of Bausch + Lomb, Bridgewater, NJ.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}